

Request for proposal (RFP)



For the determination of disulfide bridging in JJP-1008 Drug
Product

*Project “Development of first-in-class antibody therapy for
immunotherapy in metastatic melanoma, using Companion Diagnostics
(CDx) patient stratification for treatment with the immune stimulating
anti-CD270 antibody”*

co-financed by the Medical Research Agency (Poland)

Number of RFP: 2601_T02_TSI_01

JJP Biologics
Bobrowiecka 6,
00-728, Warsaw,
Poland

Company and scientific background

JJP Biologics is a Polish biotechnological company developing innovative novel biologics for treatment of autoimmune diseases and cancer.

JJP-1008 is a monoclonal antibody against CD270 (HVEM), which antagonizes the dominant suppression of immune responses by its co-inhibitory ligands, CD272 (BTLA) and CD160.

Lead molecule and status

JJP-1008 is a S231P-stabilized humanized immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the CD270 receptor expressed in many healthy cells and to multiple CD270⁺⁺⁺ overexpressing cancers, like MM.

One of the components of JJP-1008's analytical package (within Manufacturing of GMP DS and DP to support clinical studies) is the characterization of disulfide bridging in JJP-1008 Drug Product.

Scope of Request for proposal

The scope of the Request for Proposal (RFP) including conducting a research service to determinate disulfide bridges in JJP-1008 antibody using mass spectrometry methods including:

- qualitative confirmation of the expected disulfide bridging;
- qualitative conformation that no unexpected disulfide bridges are present;
- site-specific quantification of open vs. closed disulfide linkages (considering the known limitations due to differences in proteolytic digestions and ionization efficiencies).

All analyses listed above must be conducted independently for 2 samples (GMP and Non-GMP material).

JJP Biologics will deliver the test materials:

- 2x > 0.1 mg of JJP-1008 in the final formulation buffer (GMP & nonGMP reference standard);
- amino acid sequence of JJP-1008 in FASTA format.

Deliverables:

- Full study report containing all raw data. The report must be prepared in a format agreed with JJP Biologics during the provision of the service.

Requirements for the supplier or service provider

It is required that the bidder has:

⇒ at least 5 years' experience in the field of the de novo antibody sequencing – please include information confirming of such experience together with the proposal.

Schedule

Order completion date (full study report): **no longer than 8 weeks from samples delivery.**

- Estimated* start of the work (delivery of samples) – February 2026
- Estimated* end of the work – March / April 2026

** According to the current project schedule. Due to the implementation of a research and development project with research risks, the Contracting Authority reserves the right to change the planned schedule for the execution of the work under the request for proposal.*

Criteria of choice

The decision to conclude any work order as a result of this RFP process will be based on responses. The decision-making process will consider the ability of each service provider to fulfil JJPB's needs and requirements as outlined within this RFP.

Proposals will be assessed against the following criteria:

- 100% - proposed total net price
- The number of points will be calculated according to the formula:

CN/CB*100 points

where:

CN - among the responses meeting the RFP¹ requirements, the lowest net total price

CB - net total price of the examined offer

The offer with the highest number of points will be considered the most advantageous.

Deadline for the bid submission

Deadline for submission of the offer is **06.02.2026**.

=> Proposal should be sent in a non-editable version (pdf)

Remuneration

- Please provide a total price offer in Euro or PLN*
(The total quoted price must cover all costs necessary to complete the order. Please assume no additional costs on JJP Biologics side).
- The quoted price should be divided into two components: the price for the method setup/first sample and the price for the second sample.

** If bidders' prices are given in one currency, the prices indicated by bidders will be used for comparison. If the prices are given both in PLN and in Euro, the prices converted into PLN at the exchange rate on the last day of submitting offers will be used for price comparison.*

Please be aware that due to the scientific nature of the planned project, JJP Biologics reserves the right to abandon some of the tasks indicated in the scope of the request. JJP Biologics reserves also the right to make substantive reasonable changes to the assumptions made regarding the subject of the RFP, which prove necessary for the proper implementation of the scope of work or their use in the ongoing project.

JJP Biologics reserves the right to terminate the Agreement at any stage of its execution in case there are indications that the research work is no longer advisable, or if it is necessary to change the scope or approach to the work carried out under the project.

JJP reserves the right to terminate or cancel the proceedings if, due to an extraordinary change of circumstances, the fulfilment of the performance would be connected with undue hardship or would threaten one of the parties with a substantial loss. This also applies to the stage after the selection of the best offer.

Contact

Questions regarding the inquiry, as well as the offer, please send to zapytaniabadania@jip.bio

Please submit RFP questions, if any, no later than 2 days before the deadline for submission.